RxDoctor Payments Data

Kendra Connell

Family · Columbus, OHNPI 1356997894

Payments from drug & device makers

$1,273in general payments, 2019–2025

Across 49 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$344
  • Johnson & Johnson$168
  • Gilead$118
  • Indivior Inc.$101
  • Novo Nordisk$95
  • Organon$80
  • plus $367 from 11 others

What the payments were for

  • Food & beverage$1,273100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,273 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$1,524
Medicare patients
25
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide42$60,860
JardianceEmpagliflozin14$23,838
OzempicSemaglutide12$20,117
EliquisApixaban16$14,143
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$8,872
Spiriva HandihalerTiotropium Bromide14$8,218
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,531
Breo ElliptaFluticasone/Vilanterol13$5,249
DuleraMometasone/Formoterol15$4,988
Albuterol Sulfate HfaAlbuterol Sulfate175$4,711
Arnuity ElliptaFluticasone Furoate15$3,075
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,352
Atorvastatin Calcium219$1,487
Gabapentin105$1,259
Levothyroxine Sodium103$1,126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$95$20,11712 claims
AstraZenecaBreztri Aerosphere$15$7,53112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →